Since securing additional funding last fall, AXIM® Biotechnologies has expanded its ongoing new drug research to include treatments for opioid addiction, irritable bowel syndrome, multiple sclerosis, psoriasis and eczema, and restless leg syndrome.
AXIM® Biotechnologies is now taking the necessary steps to begin clinical trials for the treatment of a new condition – psychosis.
The company has entered a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew® Plus CBD chewing gum product to treat drug-induced psychosis in adult patients.
The functional chewing gum will be composed of 50 mg CBD and utilizes the company’s patent on cannabinoid-based chewing gum. AXIM® hopes to demonstrate the efficacy of the company’s new chewing gum product to treat psychosis before moving on to more advanced clinical research. The University of British Columbia will work with Health Canada and their own ethics board to design the parameters of the upcoming clinical trial
50 mgs seems low but I’m not an expert on these things.
You never know with CBD, if it works or not. It works for some epilepsy patients but there’s not much proof to convince me CBD is good for schizophrenia.
I have a bottle of CBD in my cupboard. I’m going to try it one day when I’m paranoid, that way I can see how it effects me. I take antipsychotics and other things so there hasn’t been any real need for me to take cbd yet.
Yeah, perhaps they will be able to make a stronger synthetic version, or maybe just distill it down more. I think part of the reason it’s so many pills is just because, for the reasons most people take CBD, 1 or 2 pills is fine. So that is how they are manufactured.